Page 2 - Laura Gault News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sage Therapeutics Announces U S Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington s Disease Seite 1

18.10.2023 - Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to SAGE-718 for the . Seite 1

United statesLaura gaultSage therapeutics incDrug administrationOffice of orphan products developmentSage therapeuticsOrphan drug designationChief medical officerOrphan products developmentOrphan drug actSage therapeutics chartAge therapeutics kursAge therapeutics aktie

Sage Therapeutics Implements Strategic Reorganization to Support Plans for ZURZUVAE™ Commercial Launch and Pipeline Advancement

Potential growth catalysts include planned 4Q 2023 launch of ZURZUVAE and expected data read-outs for SAGE-718 and SAGE-324 in 2024 Approximately 40% workforce reduction supports focus on agile.

Jim dohertyLaura gaultBarry greeneAl robichaudChris benecchiDiscovery researchExchange commissionClinical developmentSage therapeutics incOsage researchSage therapeuticsChief executive officerChief scientific officerMedicinal chemistryPre clinical scientific advisoryMike quirk

SAGE Therapeutics (SAGE) Implements Strategic Reorganization to Support Plans for ZURZUVAE Commercial Launch

SAGE Therapeutics (SAGE) Implements Strategic Reorganization to Support Plans for ZURZUVAE Commercial Launch
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Jim dohertyChris benecchiMatthew hensonLaura gaultAshley kaplowitzAl robichaudBarry greeneSage therapeutics incClinical developmentExchange commissionDiscovery researchOsage researchSage therapeuticsChief executive officerChief scientific officerMedicinal chemistry

Sage cuts 40% of staff in portfolio shake-up (NASDAQ:SAGE)

Sage cuts 40% of staff in portfolio shake-up (NASDAQ:SAGE)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomJim dohertyLaura gaultAl robichaudChris benecchiDiscovery researchChief scientific officer al robichaudChief development officer jim dohertyMike quirkChief scientific officerChief medical officerChief business officerMedical affairsMark pollack

Sage Therapeutics to lay off about 40 percent of its workforce

The job cuts come after the FDA gave only limited approval to the Cambridge company’s new treatment for depression.

United statesLaura gaultChris benecchiJim dohertyAl robichaudDrug administrationCenters for diseaseNational institute of mental healthMike quirkMark pollackDisease controlNational institute